Memphis Meats rolls out first lab-grown poultry

Lab-grown meat producer Memphis Meats has announced the production of the world’s first ‘clean’ chicken and duck.

While a few companies, including Memphis Meats, have produced clean – commonly known as lab-grown – beef, it is believed that this is the first time clean poultry has been created.

“It is thrilling to introduce the first chicken and duck that didn’t require raising animals. This is a historic moment for the clean meat movement,” said Uma Valeti, co-founder and CEO of Memphis Meats. “Chicken and duck are at the centre of the table in so many cultures around the world, but the way conventional poultry is raised creates huge problems for the environment, animal welfare, and human health. It is also inefficient.

“We aim to produce meat in a better way, so that it is delicious, affordable and sustainable. We really believe this is a significant technological leap for humanity, and an incredible business opportunity — to transform a giant global industry while contributing to solving some of the most urgent sustainability issues of our time.”

The multi-animal platform is expected to allow the company to produce many types of meat and to fine-tune the taste, texture and nutrition profile of its products. The platform will also enable the company to scale up production and rapidly reduce costs.

The team expects to continue reducing production costs dramatically, with a target launch of its products to consumers by 2021.

More About

BY LAURIE MCGINLEY
WASHINGTON POST
In a historic move, the Food and Drug Administration on Tuesday approved a pioneering gene therapy for a rare form of childhood blindness, the first such treatment cleared in the United States for an inherited disease.
The approval signals a new era for gene therapy, a field that struggled for decades to overcome devastating setbacks but now is pushing forward in an effort to develop treatments for hemophilia, sickle-cell anemia and an array of other genetic diseases. Yet the products, should they reach patients, are likely to carry stratospheric prices — a prospect already worrying consumer advocates and economists.
Philadelphia-based Spark Therapeutics, which makes the childhood-blindness treatment, said it will not announce the price until January. Analysts speculate it could be as much as $1 million for both eyes.

genomic privacy

BY CURTIS AND HEREWARD
THE CONVERSATION
We are approaching a time when you might be too scared to have your genome sequenced. Only last week, a US senator called for an investigation into the privacy policies of direct-to-consumer DNA companies.

There is something like gold flowing through the veins of 100-year-old Maria Tegas, and everyone wants a piece of the treasure. The centenarian, who lives in a poor and remote area of central eastern Sardinia – in one of 14 villages known to geneticists and genealogists as the Blue Zone – has not had an easy life.

professional regulation

BY TOM IRELAND
THE GUARDIAN
Josiah Zayner, 36, recently made headlines by becoming the first person to use the revolutionary gene-editing tool Crispr to try to change their own genes. Part way through a talk on genetic engineering, Zayner pulled out a syringe apparently containing DNA and other chemicals designed to trigger a genetic change in his cells associated with dramatically increased muscle mass.

BY AMY DOCKSER MARCUS
WALL STREET JOURNAL
Kian Sadeghi has postponed homework assignments, sports practice and all the other demands of being a 17-year-old high-school junior for today. On a Saturday afternoon, he is in a lab learning how to use Crispr-Cas9, a gene-editing technique that has electrified scientists around the world—and sparked a widespread debate about its use.

emerging technologies

BY LAURIE MCGINLEY
WASHINGTON POST
In a historic move, the Food and Drug Administration on Tuesday approved a pioneering gene therapy for a rare form of childhood blindness, the first such treatment cleared in the United States for an inherited disease. The approval signals a new era for gene therapy, a field that struggled for decades to overcome devastating setbacks but now is pushing forward in an effort to develop treatments for hemophilia, sickle-cell anemia and an array of other genetic diseases. Yet the products, should they reach patients, are likely to carry stratospheric prices — a prospect already worrying consumer advocates and economists.

The Associated Press
CBC.ca
Scientists for the first time have tried editing a gene inside the body in a bold attempt to permanently change a person's DNA to try to cure a disease. The experiment was done Monday in California on 44-year-old Brian Madeux.

gene patents

BY ANDRÉ PICARD
THE GLOBE AND MAIL
‘Gene patents no longer need to stand in the way of diagnosing life-threatening disease.”
That’s how Alex Munter, president and chief executive officer of the Children’s Hospital of Eastern Ontario, summed up the impact of an out-of-court settlement in the lawsuit CHEO launched against Transgenomic Inc. in 2014. Transgenomic, a biotechnology company based in Omaha, Neb., owns five gene patents related to the potentially deadly heart condition Long QT syndrome.

BY MICHAEL SLEZAK
NEWSCIENTIST
Your genes are no longer patentable in Australia. The country’s highest court found unanimously that two previous Australian judgments allowing patents of genes were wrong, and they do not constitute a patentable invention.

Search

Archives

Archives

In Case You Missed It

BY KELLY SERVICK
SCIENCE
The molecular diagnostics company Myriad Genetics has put an end to a long battle to defend controversial patents on genetic tests for cancer risk. Several of the companies Myriad was suing for patent infringement announced settlements this week, and The New York Times reports that the company is in discussions to settle the remaining suits.